Screening for prostate cancer: opportunities for prevention

Area of Science:

• Oncology
• Urology
• Preventive Medicine

Background:

• Secondary prevention of prostate cancer via early detection has limitations, including uncertain treatment benefits, detection of indolent tumors, treatment failures, and side effects.
• Primary prevention strategies like dietary changes or retinoids have shown limited feasibility.
• The 5-alpha-reductase inhibitor finasteride, approved for benign prostatic hyperplasia, presents a potential primary chemoprevention option.

Purpose of the Study:

• To evaluate the efficacy of finasteride in reducing prostate cancer incidence through primary chemoprevention.
• To assess the safety and feasibility of long-term finasteride use for prostate cancer prevention.

Main Methods:

• The Prostate Cancer Prevention Trial (PCPT) is a large-scale, randomized, placebo-controlled study.
• The trial enrolled 18,000 healthy men aged 55 and older.
• Participants were monitored over a 7-year period to assess prostate cancer development.

Main Results:

• Finasteride prophylaxis significantly reduced the incidence of prostate cancer in the study population.
• The study provided evidence for the effectiveness of 5-alpha-reductase inhibitors in prostate cancer chemoprevention.

Conclusions:

• Primary chemoprevention with finasteride is a viable strategy for reducing prostate cancer incidence.
• The findings support the use of finasteride for prostate cancer risk reduction in eligible men.